Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of TJ301 (FE 999301) Administered Intravenously in Patients With Active Ulcerative Colitis

NCT03235752 is registered in ClinicalTrials.gov with I-Mab Biopharma HongKong Limited as lead sponsor.

NCT NCT03235752
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03235752 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of TJ301 (FE 999301) Administered Intravenously in Patients With Active Ulcerative Colitis
Lead sponsor
I-Mab Biopharma HongKong Limited
Phase
Phase 2
Overall status
Completed
Start date
February 6, 2018
Completion date
December 21, 2020
Enrollment
91 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

active ulcerative colitis